References
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12 - 19
- Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796 - 802
- Kaur P, McDougall JK, Cone R. Immortalization of primary human epithelial cells coned cervical carcinoma DNA containing human papillomavirus type E6/E7 open reading frames. J Gen Virol 1989; 70:1261 - 1266
- Kaur P, McDougall JK. HPV-18 immortalization of human keratinocytes. Virology 1989; 173:302 - 310
- Percoraro G, Morgan D, Defendi V. Differential effects of human papillomavirus type 6, 16 and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci USA 1989; 86:563 - 567
- Nguyen CL, Münger K. The human papillomavirus E7 protein deregulates mitosis via an association with the Nuclear Mitotic Apparatus Protein-1 (NuMA). J Virol 2009; 83:1700 - 1707
- Kadish AS, Einstein MH. Vaccine strategies for human papillomavirus-associated cancers. Curr Opin Oncol 2005; 17:456 - 461
- Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006; 56:226 - 243
- Wang XG, Revskaya E, Bryan RA, Strickler HD, Burk RD, Casadevall A, et al. Treating cancer as an infectious disease—viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. PLoS ONE 2007; 2:e114
- Phaeton R, Wang XG, Einstein MH, Goldberg GL, Casadevall A, Dadachova E. The influence of proteasome inhibitor MG132, external radiation and unlabeled antibody on the tumor uptake and biodistribution of (188)Re-labeled anti-E6 C1P5 antibody in cervical cancer in mice. Cancer 2010; 116:1067 - 1074
- Casadevall A, Cleare W, Feldmesser M, Glatman-Freedman A, Goldman DL, Kozel TR, et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans poly-saccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother 1998; 42:1437 - 1446
- Berek JS, Dorigo O, Schultes B, Nicodemus C. Specific keynote: immunological therapy for ovarian cancer. Gynecol Oncol 2003; 88:105 - 109
- Casadevall A, Goldstein H, Dadachova E. Targeting host cells harbouring viruses with radiolabeled antibodies. Expert Opin Biol Ther 2007; 7:595 - 597
- Dadachova E, Wang XG, Casadevall A. Targeting the virus with radioimmunotherapy in virus-associated cancer. Cancer Biother Radiopharm 2007; 22:303 - 308
- Schweitzer AD, Rakesh V, Revskaya E, Datta A, Casadevall A, Dadachova E. Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to the metastatic melanoma tumors with wide range of melanin concentrations. Melanoma Res 2007; 17:291 - 303
- Kehmeier E, Rühl H, Voland B, Stöppler MC, Androphy E, Stöppler H. Cellular steady-state levels of “high risk” but not “low risk” human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome dependent degradation independent of their p53- and E6AP-binding capabilities. Virology 2002; 299:72 - 87
- Oh KJ, Kalinina A, Wang J, Nakayama K, Nakayama KI, Bagchi S. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J Virol 2004; 78:5338 - 5346
- Revskaya E, Jongco AM, Sellers RS, Howell RC, Koba W, Guimaraes AJ, et al. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Clin Cancer Res 2009; 15:2373 - 2379
- Chen F-M, Taylor CR, Epstein AL. Tumor necrosis treatment of me-180 human cervical carcinoma model with 13ii-labeled tnt-1 monoclonal antibody. Cancer Res 1989; 49:4578 - 4585